Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CAIV-T 10^7 · 1 trial · 1 indication
The immune responses were evaluated by hemagglutination inhibition assay (HAI) on serum samples.
| Arm | Type | Description |
|---|---|---|
| CAIV-T 10^5 | EXPERIMENTAL | a single intranasal 0.2 mL dose of liquid CAIV-T 10\^5 (approximately 0.1 mL into each nostril) |
| CAIVT 10^7 | EXPERIMENTAL | A single intranasal 0.2 mL dose of liquid CAIV-T 10\^7 (approximately 0.1 mL into each nostril) |
| Placebo | PLACEBO_COMPARATOR | A single intranasal 0.2 mL dose of placebo |
| Trivalent inactivated vaccine (TIV) | ACTIVE_COMPARATOR | A single intramuscular injection of commercially available vaccine |
| Name | Type | Description |
|---|---|---|
| CAIV-T 10^7 | BIOLOGICAL | a single intranasal 0.2 mL dose of liquid CAIV-T 107 (approximately 0.1 mL into each nostril) |
| CAIVT 10^5 | BIOLOGICAL | a single intranasal 0.2 mL dose of CAIV-T \<10\^5 |
| Placebo | BIOLOGICAL | a single intranasal 0.2 mL dose of placebo |
| TIV | BIOLOGICAL | commercially available TIV injected intramuscularly |
Inclusion Criteria: * children at least 6 months of age and less than 36 months of age at the time of enrollment, and in good health as determined by medical history, physical examination and clinical judgement; * whose parent/legal guardian has provided written informed consent after the nature of...
CAIV-T 10^7 is an investigational liquid formulation of an influenza virus vaccine being studied for the prevention of influenza. It is being developed by AstraZeneca PLC (AZN) and is currently in Phase 2 clinical development. The vaccine is intended for use in healthy children.
CAIV-T 10^7 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting clinical trials to evaluate this influenza vaccine candidate in pediatric populations.
CAIV-T 10^7 is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 2 trial has been completed, and the drug remains under evaluation for its safety and immunogenicity.
CAIV-T 10^7 has been studied in one completed Phase 2 clinical trial, registered as NCT00192322. This trial investigated immune responses elicited by a liquid formulation of the influenza virus vaccine in healthy children aged 6 months and older in the United States.
CAIV-T 10^7 is an investigational liquid formulation of an influenza virus vaccine. It is designed to elicit immune responses against influenza in healthy children. The drug is still in clinical development and has not been approved for public use.